Pazopanib in renal cell carcinoma.
Author(s): Ward JE, Stadler WM.
Affiliation(s): University of Chicago, Chicago, Illinois 60637, USA.
Publication date & source: 2010, Clin Cancer Res. , 16(24):5923-7
Pazopanib is an oral, multitargeted tyrosine kinase inhibitor that has been
approved by the U.S. Food and Drug Administration for treatment of patients with
advanced renal cell cancer on the basis of a randomized, double-blind,
placebo-controlled, phase III trial, which showed that once a day dosing of 800
mg of pazopanib resulted in progression free survival of 9.2 months versus 4.2
months (P < 0.0001). Pazopanib thus joins sorafenib and sunitinib as one of the
clinically available VEGF receptor (VEGFR)-targeted drugs for the treatment of
patients with advanced clear cell renal cell cancer. The mechanism of action,
preclinical and clinical data, and a comparison with the other drugs in its class
are outlined below.
|